Cyclophosphamide News and Research

RSS
Cyclophosphamide is a drug that is used to treat many types of cancer and is being studied in the treatment of other types of cancer. It is also used to treat some types of kidney disease in children. Cyclophosphamide attaches to DNA in cells and may kill cancer cells. It is a type of alkylating agent. Also called CTX and Cytoxan.

Cyclophosphamide is a synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.
Genentech, Biogen announce FDA approval of Rituxan to treat follicular lymphoma

Genentech, Biogen announce FDA approval of Rituxan to treat follicular lymphoma

28 Jan 2011
ZIOPHARM's darinaparsin receives EMA COMP orphan drug designation for treatment of peripheral T-cell lymphoma

ZIOPHARM's darinaparsin receives EMA COMP orphan drug designation for treatment of peripheral T-cell lymphoma

20 Jan 2011
FOLOTYN Phase 2 peripheral T-cell lymphoma study results published in Journal of Clinical Oncology

FOLOTYN Phase 2 peripheral T-cell lymphoma study results published in Journal of Clinical Oncology

20 Jan 2011
Intrexon Corporation, ZIOPHARM enter partnership to develop, commercialize DNA-based therapeutics

Intrexon Corporation, ZIOPHARM enter partnership to develop, commercialize DNA-based therapeutics

7 Jan 2011
Dosing initiated in combination Phase I study of palifosfamide with etoposide and cisplatin/carboplatin in SCLC

Dosing initiated in combination Phase I study of palifosfamide with etoposide and cisplatin/carboplatin in SCLC

29 Dec 2010
Response Genetics presents two gene expression analysis for personalized cancer tharapy selection

Response Genetics presents two gene expression analysis for personalized cancer tharapy selection

14 Dec 2010
GeparQuinto study data on bevacizumab plus chemotherapy in early breast cancer to be presented at 33rd CTRC-AACR

GeparQuinto study data on bevacizumab plus chemotherapy in early breast cancer to be presented at 33rd CTRC-AACR

13 Dec 2010
Xeloda may reduce recurrence of faster growing breast cancers: Study

Xeloda may reduce recurrence of faster growing breast cancers: Study

13 Dec 2010
Novelos NOV-002 demonstrates positive results in Phase 2 neoadjuvant breast cancer trial

Novelos NOV-002 demonstrates positive results in Phase 2 neoadjuvant breast cancer trial

13 Dec 2010
Researchers present Phase III study of neoadjuvant therapy with trastuzumab and lapatinib for early breast cancer

Researchers present Phase III study of neoadjuvant therapy with trastuzumab and lapatinib for early breast cancer

13 Dec 2010
Obesity is associated with worse outcomes in patients with ER-positive/HER2-negative disease

Obesity is associated with worse outcomes in patients with ER-positive/HER2-negative disease

10 Dec 2010
Preclinical data of ZIO-101 in various lymphoma models presented at ASH 2010

Preclinical data of ZIO-101 in various lymphoma models presented at ASH 2010

6 Dec 2010
Allos Therapeutics reports new analysis of PROPEL trial data of FOLOTYN in patients with refractory PTCL

Allos Therapeutics reports new analysis of PROPEL trial data of FOLOTYN in patients with refractory PTCL

6 Dec 2010
Genentech, Biogen report Phase III study data of Rituxan in patients with advanced follicular lymphoma

Genentech, Biogen report Phase III study data of Rituxan in patients with advanced follicular lymphoma

6 Dec 2010
Research reveals new standard treatment options for various forms of lymphoma

Research reveals new standard treatment options for various forms of lymphoma

6 Dec 2010
Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

6 Dec 2010
Pivotal PROPEL trial data of FOLOTYN in patients with refractory PTCL reported at ASH Annual Meeting

Pivotal PROPEL trial data of FOLOTYN in patients with refractory PTCL reported at ASH Annual Meeting

6 Dec 2010
New standard treatment for early stage breast cancer

New standard treatment for early stage breast cancer

4 Dec 2010
Accentia enters strategic agreement with Baxter to purchase Cytoxan drug

Accentia enters strategic agreement with Baxter to purchase Cytoxan drug

29 Nov 2010
Allos Therapeutics to present FOLOTYN data for blood cancers at ASH Annual Meeting

Allos Therapeutics to present FOLOTYN data for blood cancers at ASH Annual Meeting

20 Nov 2010

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback